International AIDS Society
International AIDS Society
 
 
   

Industry Liaison Forum



The International AIDS Society-Industry Liaison Forum (IAS-ILF) is a mechanism to inform and support collaboration and partnership between industry and the IAS. Guided by a strong, multi-stakeholder advisory group, it performs this broad task by regularly providing opportunities for industry to understand the IAS’s interests and priorities, and vice versa, seeking common ground to enhance the impact of our response to HIV and related co-morbidities.







What's New


IAS-ILF symposium at INTEREST
Expanding access to viral load monitoring in resource-limited settings

This symposium, held in conjunction with the 8th INTEREST Workshop 2014 in Lusaka, Zambia, provided an occasion to discuss how to expand access to VL monitoring in resource-limited settings (RLS) and to maximize the benefits, in line with the 2013 WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. The session highlighted challenges and solutions in expanding access to VL monitoring. The first two presentations gave an overview of the clinical and financial arguments regarding routine VL monitoring, and the third presentation highlighted laboratory challenges. Following a community perspective to help contextualize this information, a panel discussed solutions to overcome implementation barriers.

The meeting agenda, report and presentations are available for download here.





2013 Annual Report

The IAS-ILF 2013 Annual Report is now available for download.




IAS-ILF Corporate Partners












 







A list of previous sponsoring industry partners is available here.

 

  Facebook Twitter LinkedIn
News

10 October 2014
New fixed-dose combination drugs now eligible for 5 years of exclusivity, FDA says

10 October 2014
Harvoni, a hepatitis C drug from Gilead, receives FDA approval

9 October 2014
WHO-WIPO-WTO joint symposium on Innovation and access to medical technologies (5 November 2014, Geneva, Switzerland)

7 October 2014
Bristol-Myers gives up on hepatitis C combination in USA

30 September 2014
Invitation to manufacturers and suppliers of medicinal products for HIV infection and related diseases, including treatment for hepatitis B and C, to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Team

25 September 2014
The Medicines Patent Pool Adds New Sub-Licensing Agreements to Improve Access to Novel ARVs in Developing Countries

23 September 2014
World Health Organization Issues Prequalification of BD FACSPresto Near-Patient CD4 Counter System for HIV/AIDS Monitoring

23 September 2014
Alere to Support Organisation of African First Ladies Against HIV/AIDS (OAFLA) in New Effort to End Mother-to-Child Transmission of HIV and Syphilis

16 September 2014
The IAS-Industry Liaison Forum (IAS-ILF) thanks its outgoing co-chairs: Celia Christie-Samuels (IAS Governing Council) and Sandra Lehrman (Merck); welcomes its two new co-chairs: Kenneth Mayer (IAS Governing Council) and Scott Purdon (ViiV Healthcare)

9 September 2014
NIH Launches Online Database of International Clinical Research Regulations

3 September 2014
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) launches a new round of research grants for 2015

22 August 2014
ViiV Healthcare receives FDA approval for Triumeq

24 July 2014
IAS and ViiV prioritise paediatric HIV research: £1.5 million additional funding from ViiV Healthcare enables the programme expansion

24 July 2014
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)

17 July 2014
The Medicines Patent Pool Signs A Record Seven New Sub-Licences to Speed the Availability of Generic HIV Medicines to Developing Countries

13 June 2014
The IAS adds its support to call for Hepatitis B birth dose

27 May 2014
The International AIDS Society announces the appointment of new Executive Director, Owen Ryan

6 march 2014
The International AIDS Society (IAS) announces a new grant of £500,000 from ViiV Healthcare to support its Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)

Articles from previous years are available here